Open-​label, Phase 3b study to evaluate effectiveness, safety and pharmacokinetic parameters of metreleptin in patients under 6 years of age with generalised lipodystrophy and associated diabetes mellitus and/or hypertriglyceridaemia.

Further information: Study Details | Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy | ClinicalTrials.gov

A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy.

A 52-week randomized, double-​blind, placebo controlled, multi-​center Phase 2b study with a 52-week blinded extension assessing safety and efficacy of frexalimab, a CD40L antagonist
monoclonal antibody, for preservation of pancreatic β-​cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy

Further information: Study Details | FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) | ClinicalTrials.gov

A Randomized, Double-blind, 2-arm, Phase 3 Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Newly Diagnosed Stage 3 Type 1 Diabetes (T1D)

Further information: Study Details | NCT07088068 | A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | ClinicalTrials.gov

An Open-Label Study of Mibavademab (REGN4461), a Leptin Receptor Agonist, for the Treatment of Monogenic Obesity Due to Biallelic Loss of Function Variants of the LEP Gene

Further information: Study Details | NCT07220772 | A Study EvaluatingMibavademab Treatment ofObesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | ClinicalTrials.gov

Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice

Further information: Study Details | NCT07302802 | Efficacyof Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With MonogenicObesity in Clinical Practice | ClinicalTrials.gov

Efficacy and Safety of Tirzepatide Once Weekly versus Placebo for the Treatment of Obesity
and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo-
Controlled Trial

Further information

Weight maintenance in adolescents with obesity; long-term treatment with semaglutide 2.4mg s.c. once-weekly.

Further information: Study Details | STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss | ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melanocortin-4 Receptor Pathway
Further information

An interventional, randomised, double-blind, parallel group, placebo-controlled, multi-national clinical study period.
Long-term safety and efficacy of semaglutide s.c. once-weekly on weight management in children and adolescents (aged 6 to <18 years) with obesity or overweight
Further information
 

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity

A Trial Comparing the Effect and Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® in Children With Growth Hormone Deficiency
Further information
 

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin.
Further information

A Registry of Patients with Biallelic Pro-Opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1), or Leptin Receptor (LEPR) Deficiency Obesity, or Bardet-Biedl Syndrome (BBS), Treated with Setmelanotide

Observational study on the treatment of patients with paediatric indications such as growth hormone deficiency (GHD), small for gestational age (SGA), Ullrich-Turner syndrome (UTS) and prepubertal patients with chronic kidney disease (CRI) as well as replacement therapy in adults with pronounced growth hormone deficiency (AGHD) with rh-GH (recombinant human growth hormone) Saizen®.

• ECLip Registry
• iDSD and DSD Registry
• Registry for patients with hypothyroidism
• Registry for patients with adrenogenital syndrome (AGS)
• Diabetes patient progress documentation (DPV)
• Structured pre- and aftercare programme after bariatric surgery
• Register for patients with extreme obesity
•  iGO Registry: Registry for patients with monogenic obesity
• FeProCAYA: fertility protection for children and adolescents in paediatric oncology

• Diabetes and social jet lag
•  BMBF - JA Study
• Ulm Paediatric Study
• Pfizer Registry of Outcomes in Growth hormone RESearch (PROGRES)

 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed with Type 1 Diabetes Aged ≥1 to <36 Years